B. Hansen

发表

Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation

Sadik H. Kassim, W. Telford, S. Rosenberg, 2013 .

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

S. Rosenberg, J. Gea-Banacloche, S. Feldman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.

Michael L. Wang, M. Stetler-Stevenson, D. Stroncek, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and feasibility of anti-CD19 CAR T cells with fully-human binding domains in patients with B-cell lymphoma

S. Rosenberg, P. Youkharibache, D. Stroncek, 2019, Nature Medicine.

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

Sadik H. Kassim, W. Telford, S. Rosenberg, 2013, Blood.

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses

S. Steinberg, A. Fojo, B. Levine, 2015, Clinical Cancer Research.

Safety and feasibility of anti-CD19 CAR T cells with fully-human binding domains in patients with B-cell lymphoma

S. Rosenberg, P. Youkharibache, D. Stroncek, 2019, Nature Medicine.

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

Syed Abbas Ali, Michael Wang, Michael L. Wang, 2016, Blood.

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor with a CD28 Costimulatory Moiety Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Michael L. Wang, M. Stetler-Stevenson, D. Stroncek, 2017 .

Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor

Michael L. Wang, M. Stetler-Stevenson, D. Stroncek, 2015 .

T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial

S. Pittaluga, M. Bagheri, D. Stroncek, 2016 .

acute rejection after liver transplantation cytotoxic T lymphocyte antigen 4 influence the rate Polymorphisms in the T cell regulatory gene

D. Adams, J. Meurs, L. Moons, 2006 .

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses

S. Steinberg, A. Fojo, B. Levine, 2015, Clinical Cancer Research.